Citric acid

Heartland Catfish Company Eliminates Phosphate-Based Additive

Retrieved on: 
Tuesday, November 29, 2022

As the largest vertically integrated U.S. farm-raised catfish producer, Heartland Catfish is the industrys first choice for Individually Quick Frozen (IQF) catfish.

Key Points: 
  • As the largest vertically integrated U.S. farm-raised catfish producer, Heartland Catfish is the industrys first choice for Individually Quick Frozen (IQF) catfish.
  • Founded in 1996, Heartland Catfish Company has grown into the countrys largest U.S. Farm-Raised Catfish producer and processor and is located in Itta Bena, Miss.
  • Owned by the Tackett Family of Tackett Fish Farms, Heartland Catfish Company is the largest single producer of farm-raised catfish in the United States and sells fresh and frozen catfish products to retailers and restaurants around the country.
  • Follow Heartland Catfish Company on Facebook , Twitter , LinkedIn and Instagram and visit heartlandcatfish.com to learn more.

The Third World Lemon Industry Development Conference Kicked Off in Anyue, China

Retrieved on: 
Friday, November 25, 2022

ANYUE, China, Nov. 24, 2022 /PRNewswire/ -- On November 25, the Third World Lemon Industry Development Conference opened in Anyue County, Sichuan Province.

Key Points: 
  • ANYUE, China, Nov. 24, 2022 /PRNewswire/ -- On November 25, the Third World Lemon Industry Development Conference opened in Anyue County, Sichuan Province.
  • According to the organizer of the conference, Anyue County People's Government, 10 activities will be held during the conference, including the lemon industrial innovation and development summit, the roundtable conference on "building the circle and strengthening the chain" for the development of the world lemon industry, the international lemon partners conference and the special presentation for promotion of Anyue lemon industry investment.
  • In addition to more than 200 kinds of lemon products, such as dried lemon slices, lemon essential oil, lemon perfume, lemon facial mask, lemon drinks and lemon detergent, Anyue people also integrate lemon into Sichuan cuisine and have the "lemon feast" with unique flavor introduced, such as Anyue lemon flavored crispy fish, lemon chicken tofu pudding, lemon egg tarts, and lemon shrimp sashimi, bringing the value of Anyue lemon to the extreme.
  • In the future, Anyue County will digitalize the cultivation of premium lemon varieties and quality improvement to enable high-quality development of Anyue lemon with science and technology, striving for a world-famous brand of Anyue lemon.

Worldwide Citric Acid Industry to 2027 - Featuring Archer Daniels Midland, Cargill, RZBC and Weifang Ensign Industry Among Others - ResearchAndMarkets.com

Retrieved on: 
Thursday, November 24, 2022

The global citric acid market reached a volume of 2.7 million Tons in 2021.

Key Points: 
  • The global citric acid market reached a volume of 2.7 million Tons in 2021.
  • Citric acid is a weak organic acid found in the juice of lemons and other citrus fruits.
  • Around 75% of the global consumption of citric acid is accounted by the food and beverages industry, primarily as an acidulant in carbonated soft drinks.
  • As citric acid provides a less harmful formulation than phosphates in water systems, it is gaining traction among detergent manufacturers.

Gelesis Reports Upcoming Participation in Wolfe Research’s Annual Consumer Growth Conference

Retrieved on: 
Monday, November 21, 2022

Gelesis Holdings, Inc. (NYSE: GLS) (Gelesis or the Company), the maker of Plenity for weight management, today announced that its Chief Operating & Commercial Officer, David Pass, Pharm.D., will be featured in a panel discussion at Wolfe Researchs virtual Consumer Growth Conference.

Key Points: 
  • Gelesis Holdings, Inc. (NYSE: GLS) (Gelesis or the Company), the maker of Plenity for weight management, today announced that its Chief Operating & Commercial Officer, David Pass, Pharm.D., will be featured in a panel discussion at Wolfe Researchs virtual Consumer Growth Conference.
  • View the full release here: https://www.businesswire.com/news/home/20221121005103/en/
    Plenity is inspired by nature and FDA cleared to aid in weight management.
  • (Photo: Business Wire)
    To listen to the live event or to schedule a meeting, please contact your Wolfe representative.
  • Gelesis Holdings Inc. (NYSE: GLS) (Gelesis) is a consumer-centered biotherapeutics company and the maker of Plenity, which is inspired by nature and FDA cleared to aid in weight management.

Gelesis to Report Third Quarter 2022 Financial Results on November 14, 2022

Retrieved on: 
Monday, November 7, 2022

Gelesis Holdings, Inc. (NYSE:GLS) (Gelesis or the Company), the maker of Plenity for weight management, today announced that the Company will report financial results for the third quarter ended September 30, 2022, on November 14, 2022 prior to the market open.

Key Points: 
  • Gelesis Holdings, Inc. (NYSE:GLS) (Gelesis or the Company), the maker of Plenity for weight management, today announced that the Company will report financial results for the third quarter ended September 30, 2022, on November 14, 2022 prior to the market open.
  • Gelesis management will host a live conference call and webcast at 8:30 a.m.
  • View the full release here: https://www.businesswire.com/news/home/20221107005166/en/
    Gelesis is a consumer-centered biotherapeutics company and the maker of Plenity for weight management.
  • (Photo: Business Wire)
    The live call can be accessed via webcast on the Events & Presentations section of the Gelesis Investor Relations website at https://ir.gelesis.com/ .

Data Presented at Obesity Week Demonstrate that Gelesis Investigational Clinical-Stage Oral Superabsorbent Hydrogel Gel-B Preferentially Enhances the Growth of Akkermansia muciniphila in Preclinical Models Compared to Prebiotics

Retrieved on: 
Wednesday, November 2, 2022

Gelesis Holdings Inc. (NYSE: GLS) (Gelesis or the Company) the maker of Plenity for weight management, today released new data at Obesity Week in San Diego.

Key Points: 
  • Gelesis Holdings Inc. (NYSE: GLS) (Gelesis or the Company) the maker of Plenity for weight management, today released new data at Obesity Week in San Diego.
  • The group found that A. muciniphila grows in the presence of Gel-B as early as two weeks post-treatment.
  • These data are an important step forward in understanding how oral superabsorbent hydrogels induce beneficial changes to the microbiome.
  • We are looking forward to conducting further studies in this area to understand how these changes will translate to humans, said Elaine Chiquette, Gelesis Chief Scientific Officer.

Evofem Reports Top-Line Results from Phase 3 EVOGUARD Clinical Trial Evaluating EVO100 for Prevention of Chlamydia and Gonorrhea Infection in Women

Retrieved on: 
Wednesday, October 12, 2022

SAN DIEGO, Oct. 11, 2022 /PRNewswire/ -- Evofem Biosciences, Inc. (OTCQB: EVFM) announced today that the recently completed Phase 3 EVOGUARD clinical trial evaluating EVO100 for the prevention of chlamydia and gonorrhea infection in women did not achieve its endpoints.

Key Points: 
  • SAN DIEGO, Oct. 11, 2022 /PRNewswire/ -- Evofem Biosciences, Inc. (OTCQB: EVFM) announced today that the recently completed Phase 3 EVOGUARD clinical trial evaluating EVO100 for the prevention of chlamydia and gonorrhea infection in women did not achieve its endpoints.
  • "We are disappointed that EVO100 did not achieve the desired outcome in this STI clinical trial, despite the data observed in our prior study," said Saundra Pelletier, Chief Executive Officer of Evofem.
  • "As clinical study lead for the Phase 2b/3 AMPREVENCE STI trial and the Phase 3 EVOGUARD trial, I believe the study environment changed significantly from the AMPREVENCE trial to the EVOGUARD trial, specifically subject risk behaviors as well as site and CRO turnover.
  • The EVOGUARD trial was a Phase 3, double-blind, placebo-controlled efficacy trial of Phexxi vaginal gel for the prevention of urogenitalChlamydia trachomatis(CT) andNeisseria gonorrhoeae(GC) infection.

Evofem Biosciences Announces Approval of Phexxi in Nigeria

Retrieved on: 
Thursday, October 6, 2022

SAN DIEGO, Oct. 6, 2022 /PRNewswire/ -- Evofem Biosciences, Inc., (OTCQB: EVFM) today announced that its hormone-free contraceptive vaginal gel has been approved by the Nigerian Regulatory Agency NAFDAC (National Agency for Food and Drug Administration and Control). 

Key Points: 
  • Nigeria is the most populous country in Africa and the seventh largest country in the world, with 45 million women of reproductive age.
  • "We expect Nigeria will be one of many commercial markets around the world in which Evofem can generate shareholder returns while favorably impacting the lives of women," said Jenny Yip, Managing Partner at Adjuvant Capital and a Director of Evofem Biosciences.
  • Evofem is grateful to DKT Nigeria, its distribution partner in Nigeria, for their support of this registration.
  • Evofem Biosciences, Inc. is developing and commercializing innovative products to address unmet needs in women's sexual and reproductive health.

Tranont Launches First Skincare Product in Planned Expansion of Beauty Line

Retrieved on: 
Tuesday, October 4, 2022

LEHI, Utah, Oct. 04, 2022 (GLOBE NEWSWIRE) -- Tranont, a leader in high-quality health products, has released its first skincare product: Rejuvenate, an advanced hydrating serum.

Key Points: 
  • LEHI, Utah, Oct. 04, 2022 (GLOBE NEWSWIRE) -- Tranont, a leader in high-quality health products, has released its first skincare product: Rejuvenate, an advanced hydrating serum.
  • Already known for beauty products that set a foundation for healthy skin, such as collagen, Rejuvenate shows Tranont's commitment to helping people look and feel their best by nurturing their natural beauty.
  • And the early demand for it in the marketplace validates the need," said President and Tranont Owner Scott Bland.
  • Tranont is a health company that combines high-quality, clean products, wealth education, and entrepreneurial opportunity to change life for good.

Evofem Biosciences Announces Uplisting to OTCQB

Retrieved on: 
Monday, October 3, 2022

SAN DIEGO, Oct. 3, 2022 /PRNewswire/ -- Evofem Biosciences, Inc.,(OTCQB: EVFM) announced today that the trading of its common shares has been upgraded to the OTCQB Venture Market from the OTC Pink Open Market.

Key Points: 
  • SAN DIEGO, Oct. 3, 2022 /PRNewswire/ -- Evofem Biosciences, Inc.,(OTCQB: EVFM) announced today that the trading of its common shares has been upgraded to the OTCQB Venture Market from the OTC Pink Open Market.
  • The OTCQB Venture Market provides investors an exchange-comparable information experience with convenient trading through their preferred broker or financial advisor.
  • Evofem Biosciences, Inc. is developing and commercializing innovative products to address unmet needs in women's sexual and reproductive health.
  • Phexxiis a registered trademark of Evofem Biosciences, Inc.